Data / Form D filings / Ophthotech Corp.
Ophthotech Corp.: Form D filings
Ophthotech Corp., a biotechnology company in New York, NY, filed 7 Form D notices with the SEC between 2009 and 2018. The latest, on November 2, 2018, reports $11.4 million sold of a $11.7 million offering to 2 investors.
Find out what Ophthotech Corp. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ONE PENN PLAZA, 35TH FLOOR, New York, NY, 10119
- Phone
- (212) 845-8200
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1410939
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2018 | New notice | $11,694,883 | $11,399,894 | $294,989 | 2 | Oct 30, 2018 | sec.gov |
| Jun 3, 2013 | New notice | $50,000,000 | $16,666,668 | $33,333,332 | 7 | May 23, 2013 | sec.gov |
| Mar 19, 2013 | New notice | $1 | $1 | $0 | 1 | Mar 15, 2013 | sec.gov |
| Jan 3, 2013 | New notice | $1 | $1 | $0 | 1 | Dec 24, 2012 | sec.gov |
| Jul 3, 2012 | New notice | $1 | $1 | $0 | 1 | Jun 20, 2012 | sec.gov |
| Dec 18, 2009 | New notice | $30,000,000 | $15,000,000 | $15,000,000 | 7 | Dec 11, 2009 | sec.gov |
| Oct 19, 2009 | New notice | $3,000,000 | $3,000,000 | $0 | 5 | Oct 14, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| David Pritchett Redlick | Director | |
| Michael Ross | Director | |
| Keith Pritchett Westby | Executive Officer | |
| David Pritchett Carroll | Executive Officer | |
| Thomas Dyrberg | Director | |
| Glenn Sblendorio | Executive Officer, Director | |
| Axel Bolte | Director | |
| Jane Pritchett Henderson | Director | |
| David Guyer | Executive Officer, Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Oct 29, 2018 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Ophthotech Corp. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.